Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

WhatsApp

- PMLiVE

CureVac announces start of phase 1 trial of modified COVID-19 mRNA vaccine candidate

Developed in collaboration with GSK, CV0501 is specifically designed to protect against the Omicron variant

- PMLiVE

JCVI publishes advice on COVID-19 vaccines ahead of autumn booster campaign

The programme was expanded in response to the Omicron variant to include everyone aged 50 and over

- PMLiVE

WHO releases interim statement on COVID-19 vaccination for children and adolescents

Only 25% of older populations have received a complete primary series of COVID-19 vaccines in lower income countries

- PMLiVE

The impact of COVID-19 on the fight against AMR

How the responses to the COVID-19 pandemic have affected antibiotic-resistant bacteria

- PMLiVE

Moderna’s Omicron booster receives MHRA approval

The booster dose can be used in adults aged 18 years and over to protect against contracting COVID-19

- PMLiVE

Lack of evidence for AstraZeneca’s COVID-19 vaccine says UK Department of Health

Charities have called on the government to reassess its decision, which could affect the immunocompromised

- PMLiVE

ONS data reveals significant decrease in COVID-19 antibodies

The latest figures have prompted calls for the government to start its autumn booster vaccination campaigns as soon as possible

- PMLiVE

ONS records a continued fall in UK COVID-19 infections

Latest figures have shown a drop in UK COVID-19 infections by more than half a million in a week

- PMLiVE

Eli Lilly to make bebtelovimab commercially available to US states from August

The COVID-19 antibody is expected to become commercially available prior to the anticipated depletion of the US government’s current available supply

regeneron headquarters

Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV

The drug was taken off the US market in January due to it being ‘highly unlikely’ to be active against the Omicron variant

- PMLiVE

Moderna secures £1.74bn deal to supply US government with updated COVID-19 vaccine

The company will supply 66 million doses of its COVID-19 vaccine booster updated for the Omicron subvariant

- PMLiVE

Pfizer and BioNTech initiate phase 2 study of ‘enhanced’ COVID-19 vaccine

The vaccine is based on a version of the spike protein that the companies hope will offer better and broader protection against the virus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links